Middle East & Africa Biologics Market Forecast to 2031 - Regional Analysis - by Product, Application, Source, and Manufacturing

The Middle East & Africa biologics market was valued at US$ 5.81 billion in 2023 and is expected to reach US$ 17.93 billion by 2031; it is estimated to register a CAGR of 15.1% from 2023 to 2031.

Strategic Initiatives by Companies Bolster Middle East & Africa Biologics Market

Companies operating in the biologics market focus on strategic developments such as expansions, partnerships, agreements, collaborations, and new product launches, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. A few of the noteworthy developments in the biologics market are mentioned below.

In March 2024, Selvita SA expanded its services portfolio with the addition of comprehensive therapeutic antibody discovery and development capabilities to enter into the field of biologics discovery and development.

In March 2024, Bristol Myers Squibb received approval from the US FDA for Breyanzi, the first and only CAR-T cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

In February 2024, Takeda and Biological E. Limited (BE) entered into a strategic partnership to enhance access to QDENGA multidose vials (MDVs).

In December 2023, Merck received approval from the US FDA for a new Biologics License Application (BLA) for V116, its 21-valent pneumococcal conjugate vaccine specifically designed to help prevent invasive pneumococcal diseases in adults.

In October 2023, American Type Culture Collection (ATCC) and US Pharmacopeia launched their first joint products to improve quality control and decrease risk associated with the manufacturing of vaccines and biological therapies. This initial set included six products which are highly characterized and pure genomic DNA (gDNA) from cell lines that are used in bioproduction.

In March 2023, Sandoz signed a memorandum of understanding (MoU) to build a new biologics production plant in Lendava, Slovenia. The company had plans to invest at least US$ 400 million in this project, which is one of the largest international private-sector investments in Slovenia.

Thus, product approvals, product launches, and expansion strategies are likely to bring new growth trends in the biologics market in the coming years.

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd, announced that the company signed a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson (collectively known as Janssen) that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara, in the United States of America. (Source: Biocon, Press Release, 2023)
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd announced that the company completed the integration of the acquired biosimilars business from Viatris in North America (United States and Canada) effective September 1, 2023. (Source: Biocon, Press Release, 2023)
Biodextris Inc., a subsidiary of Clean Biologics SAS, announced the development of a new industrial-scale vaccine and biologics development, manufacturing, and packaging plant (CDMO). The new facility would support companies in the development and characterization of next-generation biological products and help bridge the gap between research projects and large-scale commercial production. The project amounted to a US$ 25 million investment in indoor layout and state-of-the-art materials and equipment. (Clean Biologics, Press Release, 2023)

Middle East & Africa Biologics Market Overview

The biologics market in the Middle East & Africa is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa. The market is driven by research projects undertaken by several research institutes and the availability of infrastructure as well as facilities to support high-tech work in healthcare in the UAE and Saudi Arabia. Support by governments in these countries owing to the increasing incidence of genetic disorders and cancer also boosts the growth of the market. Healthcare facilities and infrastructure in South Africa are undergoing significant developments, which is likely to fuel the adoption of advanced technologies for the diagnosis of various conditions in a large patient population, facilitating the early commencement of effective treatment. Pharmaceutical companies from other countries are forming strategic partnerships and collaborations with local healthcare providers and research institutions to expand their presence in South Africa, which further favors the growth of the biologics market in the country.

Middle East & Africa Biologics Market Segmentation

The Middle East & Africa biologics market is categorized into product, application, source, manufacturing, and country.

Based on product, the Middle East & Africa biologics market is segmented into monoclonal antibodies, vaccine, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.

In terms of application, the Middle East & Africa biologics market is categorized into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest market share in 2023.

By source, the Middle East & Africa biologics market is bifurcated into mammalian and microbial. The mammalian segment held a larger market share in 2023.

Based on manufacturing, the Middle East & Africa biologics market is bifurcated into outsourced and in-house. The outsourced segment held a larger market share in 2023.

In terms of country, the Middle East & Africa biologics market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. South Africa dominated the Middle East & Africa biologics market share in 2023.

AbbVie Inc; Pfizer Inc; Samsung Biologics Co Ltd; ADMA Biologics, Inc.; Wuxi Biologics Inc; Catalent Inc; AGC Biologics AS; AstraZeneca Plc; Amgen Inc; Nitto Avecia; and Quality Assistance s.a. are some of the leading companies operating in the Middle East & Africa biologics market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa biologics market.
• Highlights key business priorities to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa biologics market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the Middle East & Africa biologics market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.